Close menu




September 1st, 2020 | 11:56 CEST

BioNTech, CureVac, Valeo Pharma - COVID-19 wakes up the industry

  • Covid-19
Photo credits: pixabay.com

In the past, people have accepted that it usually takes about ten years to get a vaccine on the market. Careful testing with proof of success is required for a preparation to receive approvals. Since COVID-19, the pressure to develop has increased dramatically and also the potential to close a lucrative deal, because a lot is at stake for politics and economy. The necessary tests are carried out at great expense in order not to endanger human life through a vaccination, but to protect it. There are great opportunities for investors.

time to read: 2 minutes | Author: Mario Hose
ISIN: US09075V1026 , CA91915B1085 , NL0015436031

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics
    "[...] We believe that these findings could be of great benefit in protecting at-risk patients. [...]" David Elsley, CEO, Cardiol Therapeutics

    Full interview

     

    COVID-19 product before market launch

    Valeo Pharma is a Canadian pharmaceutical company that claims to manufacture specialty pharmaceuticals and focuses on marketing innovative prescription products in its home country. Valeo Pharma primarily manufactures products for neurodegenerative diseases, oncology products and specialty products for hospitals. The company also has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

    Last week, the company released information about the launch of Hesperco in Canada. The product was developed by Ingenew Pharma and will be marketed by Valeo Pharma. Ingenew is a biopharmaceutical company focused on addressing unmet medical needs and serving patients and families affected by serious and debilitating illness. Its primary therapeutic areas of interest include oncology, neurology, urology and dermatology.

    Hesperco is a trademark of Ingenew Pharma and will be used by Valeo Pharma under a license agreement. Commenting on the partnership with Valeo, Pierre Laurin, CEO of Ingenew, said: "There is a strong scientific and medical rationale for the use of Hesperco capsules to support the immune system and potentially fight off symptoms associated with Corona viruses such as the one that causes COVID-19. Thousands of compounds have been evaluated since the start of the pandemic and the active compound in Hesperco capsules has been repeatedly reported to be one of the best candidates to interfere with the mechanisms SARS-CoV-2 uses to infect our cells. (…)"

    The Valeo team is obviously ready to market the product as soon as possible. "Pending Health Canada's approval, we are poised to proceed with the commercialization of Hesperco capsules," Valeo Pharma CEO Steve Saviuk recently stated in a press release, and continued: "Ingenew's ongoing expansion of scientific data as well as the development of new clinical data will provide further evidence of Hesperco'sTM effectiveness in providing support for the immune system." Investors in Valeo Pharma can benefit from the fact that the company's market capitalization is still well below EUR 100 million and that its potential is correspondingly high, mainly because the company does not take costly research risks but focuses on the commercialization of successful products.

    Sustainable success for the post-Corona era

    BioNTech from Germany has been in the focus of investors since the beginning of the Corona Pandemic because the company's researchers are excellently positioned to research a vaccine. It is therefore not surprising that the share has been actively traded in recent months and that the market capitalization is already in the double-digit billion range. The business with the COVID-19 vaccine will certainly also have an impact on other research areas of the company and establish new standards in the fight against cancer in the wake of the Corona Pandemic.

    Stock market launch thanks to COVID-19

    CureVac is also a German company that has made it to the world stage of the pharmaceutical industry in recent months thanks to COVID-19. The company's market value skyrocketed after the company went public. In the race for a vaccine against the Corona virus, investors may be investing according to the watering can principle in order to be among the winners. The term winner in the context of a deadly Pandemic sounds bizarre, but ultimately COVID-19 is currently making the industry faster and more efficient and bringing new stars like CureVac to the scene.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Mario Hose on January 14th, 2022 | 12:17 CET

    Natural active ingredient against Covid-19: BioNTech, Cardiol, Novavax, Valneva in focus

    • Covid-19

    At the end of the week, trading on the German stock exchanges has been rather slow so far. The German leading index DAX is quoted at a level of 15,922 points and thus around 0.01% up. The index of the second tier, MDAX, traded last at 34,626 points (-0.11%), TecDAX at 3,537 points (-0.67%) and SDAX at 15,904 points with 0.43% in the red. A study from the U.S. will influence the future development of vaccine manufacturers in connection with Covid-19, according to initial research.

    Read

    Commented by Mario Hose on January 13th, 2022 | 18:11 CET

    New research results for Covid-19: BioNTech, Cardiol, Valneva

    • Covid-19

    In the afternoon of today's trading day, the German indices extended the price losses in part after a brief recovery phase. The DAX is currently trading at 15,963 points, down around 0.41%. The psychological mark of 16,000 points was exceeded at midday in phases by more than 75 points. The MDAX last traded at 34,708 points (-0.62%), TecDAX at 3,577 points (-2.26%) and SDAX at 15,976 points with 0.66% in the red. New research results for the treatment and prevention of Covid-19 provide an exciting perspective for investors.

    Read

    Commented by Mario Hose on January 12th, 2022 | 10:53 CET

    Trading stocks after EMA warning in focus: BioNTech, Johnson + Johnson, Moderna

    • Covid-19

    On Wednesday, the German indices began with a positive sign. The German benchmark index DAX is currently quoted at a level of 16,004 points and thus around 0.04% slightly up. The companies in the second tier can also hold their ground and the MDAX last traded at 34,864 points (+0.26%), TexDAX at 3,644 points and thus 0.60% lower than the previous day. SDAX also loses and last traded at 15,969 points (-0.23%).

    Read